CEDAR KNOLLS, N.J.,
Jan. 16, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®,
the natural food product that helps build lean muscle in
conjunction with resistance training, today launched the Qurr®
Fortetropin® Challenge (the "Challenge"), a new initiative that
combines Fortetropin®-based Qurr® products with a workout and
support plan designed by an award-winning and nationally certified
personal trainer, Scott Keppel.
Joseph Mannello, Chief Executive
Officer of MYOS, commented, "This is another initiative that
reflects our commitment toward more aggressive product awareness
and acceptance. MYOS is eager to build partnerships with
leading personal trainers and fitness centers, with a view towards
reaching this key demographic."
The Challenge provides the perfect platform for people to get
back on track for their long-term fitness goals. It combines a
30-day supply of Qurr® branded shakes containing Fortetropin®,
which is clinically shown to help build lean muscle mass as part of
a strength training program, with a 30-day workout program designed
by Scott Keppel, to help shape
muscles, increase strength, and burn significant fat. The workout
regimen is designed to promote healthy eating, exercising,
consistently using Qurr® and practicing healthy habits for these 30
days, so that the regimen will become part of the user's lifestyle
and mindset.
Throughout the Challenge, users will log in to their Vimify
account (a social health and fitness app) to receive clear and
actionable lessons and habits, along with coaching and support from
Scott Keppel. Users can invite
friends, family or co-workers to monitor their progress and provide
encouragement. Users gain permanent access to the content after the
Challenge is complete.
"I am pleased to be partnering with Scott Keppel and his amazing team at Scott's
Training Systems," continued Mr. Mannello. "Scott is well-known in
the world of competition for his accomplishments in coaching
bikini, figure, fitness, and body building contestants.
Importantly, Scott shares our commitment to empowering individuals
to create a healthy lifestyle and to meet their fitness and/or
competitive goals."
For more information and to join the Qurr® Fortetropin®
Challenge, please visit: https://www.vimify.com/app/reg/group9031.
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™," is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, which has been clinically shown to increase muscle
size and lean body mass in conjunction with resistance training.
Fortetropin® is a fertilized egg yolk-based product manufactured
via a proprietary process to retain and optimize its biological
activity. MYOS believes Fortetropin® has the potential to redefine
existing standards of physical health and wellness. For more
information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr® products, the success of our
research and development, including our clinical studies, the
results of the clinical evaluation of Fortetropin® and its effects,
the ability to enter into new partnership opportunities and the
success of our existing partnerships, the ability to generate the
forecasted revenue stream and cash flow from sales of our products,
the ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-launches-30-day-qurr-fortetropin-challenge-300582324.html
SOURCE MYOS RENS Technology